Genenta Science (Nasdaq: GNTA) Email Formats

Biotechnology Research • Milan, Lombardy, Italy • 21-50 Employees

Genenta Science (Nasdaq: GNTA) Email Formats

Genenta Science (Nasdaq: GNTA) uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@genenta.com), used 46.2% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@genenta.com	46.2%
{first initial}.{last name}	j.doe@genenta.com	38.5%
{first initial}.{second initial}{last name}	j.odoe@genenta.com	15.4%

Key Contact at Genenta Science (Nasdaq: GNTA)

Stefania Mazzoleni

Director Of Program Development

Company overview

Headquarters	Via Olgettina, 58, Milan, 20132, IT
Phone number	+3908738490963
Website	genenta.com
NAICS	541714
SIC	873
Keywords	Gene Therapy, Cancer, Immunotherapy, Cell Therapy
Founded	2014
Employees	21-50
Socials

About Genenta Science (Nasdaq: GNTA)

Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first in class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated in Q4 2024 a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include combination with immune checkpoint inhibitors. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Manager

Senior

Employees by Department

Genenta Science (Nasdaq: GNTA) has 9 employees across 4 departments.

Departments

Number of employees

Funding Data

Explore Genenta Science (Nasdaq: GNTA)'s funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2022-01-31	23	N/A
2025-04-19	16	$21,900,000

Funding Insights

$21,900,000

Total funding amount

$21,900,000

Most recent funding amount

Number of funding rounds

Genenta Science (Nasdaq: GNTA) Tech Stack

Discover the technologies and tools that power Genenta Science (Nasdaq: GNTA)'s digital infrastructure, from frameworks to analytics platforms.

Apache HTTP Server

Web servers

Salesforce Marketing Cloud Account Engagement

Marketing automation

jQuery

JavaScript libraries

Contact Form 7

Form builders

PHP

Programming languages

WP Rocket

Caching

WordPress

Blogs

Divi

Page builders

OWL Carousel

JavaScript libraries

RSS

Miscellaneous

MySQL

Databases

hCaptcha

Security

Frequently asked questions

Genenta Science (Nasdaq: GNTA) is located in Milan, Lombardy, IT.

You can reach Genenta Science (Nasdaq: GNTA) at +3908738490963.

Genenta Science (Nasdaq: GNTA) was founded in 2014, making it 12 years old. The company has established itself as a significant player in its industry over this time.

Genenta Science (Nasdaq: GNTA) has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Genenta Science (Nasdaq: GNTA) has raised a total of $21,900,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.

Key Contact at Genenta Science (Nasdaq: GNTA)

Stefania Mazzoleni

Director Of Program Development

4.8

40,000 users